Active Ingredient History
Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute myelogenous leukemia. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Squamous Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 2)
Hodgkin Disease (Phase 2)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 1)
Rhabdomyosarcoma (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Stomach Neoplasms (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue